SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
inflation reduction act
Biden-Era Law That Trump Has Attacked Delivers Price Cuts for 15 More Drugs Under Medicare
"Medicare drug price negotiation is about to deliver tangible lower costs to seniors in Medicare, unlike Trump’s ceremonial events with Big Pharma CEOs in the Oval Office," said one Democratic senator.
Nov 26, 2025
The Trump administration on Tuesday announced newly negotiated prices for more than a dozen prescription drugs covered by Medicare, an achievement made possible by a Biden-era law that has faced relentless attacks from the pharmaceutical industry, GOP lawmakers, and the Republican president.
The announcement marks the end of the second round of Medicare drug price negotiations required under the Inflation Reduction Act (IRA), a measure passed in 2022 without the support of a single Republican in Congress. Last year, House GOP leaders said the law was "disastrous" and decried what they called "the mandate from bureaucrats to artificially set prescription drug prices."
The new list contains 15 drugs, including the diabetes and weight loss medication Ozempic, the breast cancer drug Ibrance, and the prostate cancer drug Xtandi. The Centers for Medicare & Medicaid Services (CMS) estimated that if the new prices—which take effect in 2027—had been in effect last year, Medicare would have saved $12 billion.
President Donald Trump campaigned on rolling back the IRA, which for the first time allowed Medicare to negotiate drug prices directly with pharmaceutical companies. Since taking office, Trump has taken steps to weaken the law, including by signing a measure that will exempt certain high-priced drugs from Medicare negotiations—a multibillion-dollar handout to Big Pharma.
But in statements on Tuesday, Trump-appointed officials hailed the newly negotiated prices. Robert F. Kennedy Jr., secretary of the Health and Human Services Department, said the negotiation results stemmed from a Trump directive to "stop at nothing to lower healthcare costs for the American people."
CMS Administrator Mehmet Oz declared that the second round of negotiations was more successful than the first, which was held under the Biden administration. Experts said that claim is specious at best.
Democratic lawmakers were quick to highlight Republican opposition to the IRA, and continued attacks on the law, in response to the newly negotiated prices.
"Democrats took on Big Pharma by giving Medicare the power to negotiate on behalf of the tens of millions of seniors that want lower drug prices while every Republican voted against it,” said Sen. Ron Wyden (D-Ore.), the top Democrat on the Senate Finance Committee. “Today’s announcement is a result of that effort by Democrats to lower health costs for older Americans."
"Medicare drug price negotiation is about to deliver tangible lower costs to seniors in Medicare, unlike Trump’s ceremonial events with Big Pharma CEOs in the Oval Office," Wyden added. "Republicans neutered future Medicare drug price negotiations by adding delays and exemptions to some of the most expensive drugs, especially cancer drugs like Keytruda."
Tuesday's announcement came less than a week after the pharmaceutical industry suffered its 16th defeat in court as it continues its legal campaign against the Medicare price negotiations. The industry is also lobbying aggressively in support of legislation that would further weaken the IRA price-negotiation provisions.
"Drug corporations already secured a $9 billion giveaway from President Trump and congressional Republicans paid for by taxpayers and cancer patients through the Big Ugly Bill, and they are trying to go even further to delay and exempt price negotiations for more blockbuster drugs," said Steve Knievel, access to medicines advocate at Public Citizen.
"Policymakers must reject these efforts to undermine Medicare drug price negotiations," Knievel added. "Instead they should build on the program’s success by providing everyone access to negotiated prices, negotiating lower prices for more drugs sooner, and ensuring drug corporations can no longer rip us off by charging the highest prices in the world for medications."
Keep ReadingShow Less
Big Pharma Army of 500 Lobbyists Is Coming for Medicare Prescription Drug Negotiations, Watchdog Warns
Lobbyists working to pass Pharma-backed legislation currently outnumber lobbyists working to oppose it by more than 20-to-1, estimates Public Citizen.
Nov 19, 2025
Government watchdog Public Citizen is warning that the pharmaceutical industry is preparing an all-out blitz aimed at sabotaging government efforts to negotiate lower prices for prescription drugs.
In a report released on Wednesday, Public Citizen said it found that the major pharmaceutical companies this year have hired more than 500 lobbyists to push for the passage of three pieces of legislation that would undermine the provisions allowing the government to negotiate lower drug prices contained in the 2022 Inflation Reduction Act.
The first piece, called the ORPHAN Cures Act, was passed by Congress in July after being stuffed into the One Big Beautiful Bill Act. According to Public Citizen, the law will "delay and exempt some of the most profitable drugs—including cancer treatments—from negotiations, representing tens of billions in annual Medicare spending."
The other two pieces of legislation—the EPIC Act and the MINI Act—have not yet been passed, and Public Citizen says that they "would lengthen the already long delay period before small molecule drugs are eligible for negotiation—effectively excluding many medicines from negotiations entirely or shortening the period patients have access to lower negotiated prices to only one or two years."
Public Citizen estimates that there are currently 501 lobbyists who are pushing to pass these laws, while just 24 lobbyists are working to block their passage. In total, notes Public Citizen, this means opponents of the legislation are outnumbered by a ratio of more than 20-to-1.
Steve Knievel, Public Citizen's access to medicines advocate, called on elected representatives to "reject the demands of pharma lobbyists and instead work to make prescription drugs more affordable" for their constituents.
"Instead of handing drug corporations billions of dollars by helping them evade price negotiations," Knievel said, "Congress should pass legislation to empower Medicare to negotiate lower drug prices on all costly medicines and allow all patients to access lower, negotiated prices, even if they don’t have Medicare."
Keep ReadingShow Less
Trump Quietly Dishes Out More Tax Breaks to Rich Investors While Slashing Food Aid for Millions
"Why would corporations spend millions on Trump's ballroom or Bitcoin? Because they're getting billions in unlegislated tax breaks," said one Democratic lawmaker.
Nov 08, 2025
The Trump administration is quietly waging an all-out regulatory war on a Biden-era corporate tax that aimed to prevent large companies from dodging their tax liabilities while reporting huge profits.
The corporate alternative minimum tax (CAMT) was enacted as part of the Inflation Reduction Act, Democratic legislation that former President Joe Biden signed into law in 2022. The CAMT requires highly profitable US corporations to pay a tax of at least 15% on their so-called book profits, the figures reported to shareholders.
As the Institute on Taxation and Economic Policy has explained: "Many of the special breaks that corporations use to avoid taxes work by allowing companies to report profits to the IRS that are much smaller than their book profits. Corporate leaders prefer to report low profits to the IRS (to reduce taxes) and high profits to the public (to attract investors)."
But since President Donald Trump took office in January, his administration has issued guidance and regulatory proposals designed to gut the CAMT. The effort is a boon to corporate giants and rich private equity investors at a time when the Trump administration is relentlessly attacking programs for low-income Americans, including Medicaid and nutrition assistance.
The New York Times reported Saturday that "with its various tax relief provisions, the administration is now effectively adding hundreds of billions of dollars in new breaks for big businesses and investors" on top of the trillions of dollars in tax cuts included in the Trump-GOP budget law enacted over the summer.
"The Treasury is empowered to write rules to help the IRS carry out tax laws passed by Congress," the newspaper added. "But the aggressive actions of the Trump administration raise questions about whether it is exceeding its legal authority."
Why would corporations spend millions on Trump's ballroom or bitcoin?
Because they're getting billions in unlegislated tax breaks.
We've gone from a system where the rich must pay taxes for public services, to one where they must pay the president for private favors.
— Tom Malinowski (@Malinowski) November 8, 2025
The administration's assault on the CAMT has drawn scrutiny from members of Congress.
In a September 8 letter to US Treasury Secretary Scott Bessent, a group of Democratic lawmakers and Sen. Angus King (I-Maine) warned that the administration's guidance notices "create new loopholes in the corporate alternative minimum tax for the largest and wealthiest corporations."
"Most troubling, Notice 2025-27, issued this June, allows companies to avoid CAMT if their income—under a simplified accounting method—is below $800 million," the lawmakers wrote. "The Biden administration previously set the safe harbor threshold precisely at $500 million in its proposed CAMT rule after calculating that a higher safe harbor threshold would risk exempting corporations that should be subject to CAMT under statute."
"Now, less than nine months later and with zero justification, this new guidance summarily asserts that an $800 million safe harbor will not run that risk," they continued. "We are seriously concerned that this cursory loosening of CAMT enforcement will simply allow more wealthy corporations to avoid paying their legally owed share."
Keep ReadingShow Less
Most Popular